Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction-Reference-Cited by-同舟云学术

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

Published:2009-12-08 Issue:100 Volume:2 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Bertotti Andrea¹,Burbridge Mike F.²,Gastaldi Stefania¹,Galimi Francesco¹,Torti Davide¹,Medico Enzo³,Giordano Silvia¹,Corso Simona¹,Rolland-Valognes Gaëlle⁴,Lockhart Brian P.⁴,Hickman John A.²,Comoglio Paolo M.¹,Trusolino Livio¹

Affiliation:

1. Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.

2. Cancer Research and Drug Discovery, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.

3. Laboratory of Functional Genomics, The Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Torino Medical School, 10060 Candiolo (Torino), Italy.

4. Division of Molecular Pharmacology and Pathophysiology, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France.

Abstract

Cells addicted to different oncogenic receptor tyrosine kinases develop common downstream mechanisms to sustain malignancy.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference57 articles.

1. Oncogene addiction: setting the stage for molecularly targeted cancer therapy

2. Gefitinib — a novel targeted approach to treating cancer

3. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

4. Epidermal growth factor receptor mutations in lung cancer

5. Comparing antibody and small-molecule therapies for cancer

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of IDH and EGFR as biomarkers in glioblastoma multiforme: A case-control study;Heliyon;2024-08

2. Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition;International Journal of Molecular Sciences;2022-05-21

3. Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy;Cell Communication and Signaling;2022-01-08

4. Drug Addiction in Cancer;Handbook of Cancer and Immunology;2022

5. The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients;Biomedicines;2021-06-10